Session » RA – Treatments Poster II: PROs, Biomarkers, & Systemic Inflammation (1223–1256)

Date: Monday, November 8, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1255

A Molecular Signature Response Classifier Predicts the Likelihood of Non-response to TNF Inhibitor Therapies in RA at 3 Months

8:30AM-10:30AM: Abstract Number: 1223

A Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease-Modifying Therapies: 6-Month Effectiveness and Patient Reported Outcome Data from the European Cohort

8:30AM-10:30AM: Abstract Number: 1250

Abatacept and Other DMARDs Have Common Transcriptomic Effects on RA Synovial Tissue

8:30AM-10:30AM: Abstract Number: 1253

Acupuncture in Rheumatoid Arthritis Activity

8:30AM-10:30AM: Abstract Number: 1248

Adjusted Analyses of the Benefits of Autoantibody Enrichment on Efficacy Outcomes in Early RA, from a Pooled Analysis of 4 Abatacept RCTs

8:30AM-10:30AM: Abstract Number: 1225

Baseline Extracellular Matrix Biomarkers Predict Abatacept Treatment Response in MTX-Naive, ACPA+ Patients with Early RA

8:30AM-10:30AM: Abstract Number: 1240

Biomarker Driven Dissection of Inflammation Modulatory Effects of Upadacitinib versus Abatacept in Patients with Active Rheumatoid Arthritis Refractory to Biologic DMARDs

8:30AM-10:30AM: Abstract Number: 1245

Characteristics of RA Patients Treated with JAK Inhibitors Before versus After VTE Warnings: Results of a Real-World Multicentric Study

8:30AM-10:30AM: Abstract Number: 1227

Clinical Predictors of Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach Using Clinical Trial Data

8:30AM-10:30AM: Abstract Number: 1241

Comparison of the Effects of Upadacitinib Monotherapy with MTX on Protein Biomarkers in MTX-Naïve and MTX-Inadequate Responders in Patients with Active Rheumatoid Arthritis: Results from the SELECT-EARLY and SELECT‑MONOTHERAPY Phase 3 Studies

8:30AM-10:30AM: Abstract Number: 1231

Consistent Impact of Autoantibody Enrichment Across All ACR Core Measures in Early Rheumatoid Arthritis Treated with Abatacept: Data from a Large Pooled Analysis of 4 Randomized Controlled Trials

8:30AM-10:30AM: Abstract Number: 1239

Differences in Patient-Reported Outcomes Between Those Who Stay in Remission and Those Who Have Disease-Worsening Following Therapy Withdrawal in Patients with Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 1252

Discontinuation of TNFi Treatment Among Rheumatoid Arthritis Patients with a Molecular Signature of Non-response to Tumor Necrosis Factor-ɑ Inhibitor Therapies

8:30AM-10:30AM: Abstract Number: 1229

Does BMI Influence the Efficacy of Subcutaneous or Intravenous Abatacept in Patients with RA in Routine Clinical Practice? A Post Hoc Analysis of Two Real-world Observational Studies

8:30AM-10:30AM: Abstract Number: 1256

Factors Associated with the Use of Biologic Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 1230

Impact of Serologic Status on Clinical Responses to Upadacitinib or Abatacept in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Biologic DMARDs: Sub-Group Analysis from the Phase 3 SELECT-CHOICE Study

8:30AM-10:30AM: Abstract Number: 1249

In Rheumatoid Arthritis, Inhibition of the Lactate Monocarboxylate Transporters-1, and -4 in Pathological Fibroblast-Like Synoviocytes Led to Decreased ChemokineProduction

8:30AM-10:30AM: Abstract Number: 1224

Low CD39 Expression on B Cells Predicts the Occurrence of Anti-Drug Antibodies in RA Patients Treated with Rituximab

8:30AM-10:30AM: Abstract Number: 1238

Low Patient Global Assessment of Disease Activity and Negative Rheumatoid Factor Are Strongly Associated with Likelihood of Maintaining Remission Following Tapering of Therapy in Patients with Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 1244

Mindfulness-Based Stress Reduction (MBSR) to Improve Patient-Related Outcomes (PROs) in Patients with Rheumatoid Arthritis in Clinical Remission but Elevated Negative PROs: A Pragmatic Pilot Study

8:30AM-10:30AM: Abstract Number: 1236

Pain in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints with Baricitinib Clinical Trials

8:30AM-10:30AM: Abstract Number: 1233

Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Registry in Canada

8:30AM-10:30AM: Abstract Number: 1247

Plasma Cell-free DNA Is a Useful Biomarker for Tocilizumab Therapy in Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 1228

Predicting RA Remission with Subcutaneous Abatacept Treatment in the Real-world Setting

8:30AM-10:30AM: Abstract Number: 1237

Predictors of Response: Baseline Characteristics and Early Treatment Responses Associated with Achievement of Remission and Low Disease Activity Among Upadacitinib-Treated Patients with Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 1243

Real World Validation of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis: Analysis from the RISE Registry

8:30AM-10:30AM: Abstract Number: 1234

Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy

8:30AM-10:30AM: Abstract Number: 1251

Serum B Cell Activating Factor Reflects Good EULAR Response to TNF Inhibition in Patients with Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 1242

Sex Differences in Treatment Response to Three Different Biological Treatments and Corticosteroids in Patients with Early Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 1232

Synovial Tissue Lymphoid Aggregates Are Associated with Response to Rituximab Therapy in Rheumatoid Arthritis Patients

8:30AM-10:30AM: Abstract Number: 1246

The Effect of Tocilizumab on miR-146a-5p and EMMPRIN/CD147 in Rheumatoid Arthritis Patients

8:30AM-10:30AM: Abstract Number: 1226

The Neuro-QOL Upper Extremity Function Scale: New Opportunities to More Reliably and Precisely Measure Self-reported Hand Function and Self-care Activities in People with RA

8:30AM-10:30AM: Abstract Number: 1254

The Role of Regulatory T Cells (CD4+CD25+FOXP3) in Methotrexate Unresponsiveness in a Cohort of Naive Rheumatoid Arthritis Patients

8:30AM-10:30AM: Abstract Number: 1235

Treatment Effect of Baricitinib on Fatigue: Mediation Analysis Results from Two Phase 3 Trials

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].